Stammdaten
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.
Unternehmen & Branche
| Name | Shuttle Pharmaceuticals Holdings, Inc. |
|---|---|
| Ticker | SHPH |
| CIK | 0001757499 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Drug Manufacturers - Specialty & Generic |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,1 Mio. USD |
| Beta | 0,72 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -11,721,669 | -7.16 | 10,475,977 | 2,254,446 | |
| 2025-09-30 | 10-Q | -2,347,302 | -1.05 | 3,542,927 | 1,394,161 | |
| 2025-06-30 | 10-Q | -3,706,465 | -3.29 | 5,504,429 | 3,605,519 | |
| 2025-03-31 | 10-Q | -3,053,007 | -0.30 | 5,310,190 | 3,285,265 | |
| 2024-12-31 | 10-K | -9,144,797 | -82.60 | 2,506,290 | 709,152 | |
| 2024-09-30 | 10-Q | -3,784,082 | -39.83 | 673,568 | -1,315,377 | |
| 2024-06-30 | 10-Q | -2,031,215 | -24.12 | 2,812,998 | 801,434 | |
| 2024-03-31 | 10-Q | -1,731,031 | -0.83 | 4,753,921 | 2,761,487 | |
| 2023-12-31 | 10-K | -6,592,723 | -3.53 | 5,951,736 | 4,055,771 | |
| 2023-09-30 | 10-Q | -1,792,754 | -0.91 | 7,375,818 | 5,609,749 | |
| 2023-06-30 | 10-Q | -2,184,372 | -1.23 | 8,837,101 | 6,935,610 | |
| 2023-03-31 | 10-Q | -975,097 | -0.07 | 10,436,514 | 6,906,468 | |
| 2022-12-31 | 10-K | -3,028,448 | -0.29 | 8,653,545 | 7,677,869 | |
| 2022-09-30 | 10-Q | -998,425 | -0.10 | 9,382,016 | 8,404,875 | |
| 2022-06-30 | 10-Q | -597,275 | -0.06 | -2,306,073 | ||
| 2022-03-31 | 10-Q | -681,839 | -1,849,563 | |||
| 2021-12-31 | 10-K | -1,152,134 | 651,641 | -1,628,132 | ||
| 2021-09-30 | 10-Q | -216,961 | -2,093,135 | |||
| 2021-06-30 | 10-Q | -346,801 | -1,972,923 | |||
| 2021-03-31 | 10-Q | -129,324 | -1,722,871 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.